Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evolus, Inc. stock logo
EOLS
Evolus
$8.91
-2.2%
$9.44
$8.65
$17.82
$587.37M1.121.00 million shs4.33 million shs
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$3.67
+0.4%
$3.73
$3.36
$7.60
$147.37M1.11,113 shs381 shs
Organogenesis stock logo
ORGO
Organogenesis
$4.53
-1.5%
$3.87
$2.28
$6.71
$583.53M1.76866,885 shs461,655 shs
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$4.37
-2.9%
$2.94
$1.11
$5.17
$587.75M2.382.43 million shs4.06 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evolus, Inc. stock logo
EOLS
Evolus
-2.20%-3.68%-3.88%-24.51%-33.06%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-1.58%-3.50%-1.45%-10.67%-39.00%
Organogenesis stock logo
ORGO
Organogenesis
-1.52%-5.03%+4.14%-12.55%+82.66%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
-2.89%+14.10%+38.29%+207.75%-2.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evolus, Inc. stock logo
EOLS
Evolus
3.6914 of 5 stars
3.50.00.03.51.83.30.6
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
2.1763 of 5 stars
3.84.00.00.00.60.00.6
Organogenesis stock logo
ORGO
Organogenesis
4.344 of 5 stars
3.32.00.04.32.74.20.6
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
3.8906 of 5 stars
4.41.00.00.03.65.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$23.75166.55% Upside
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
3.50
Strong Buy$12.00227.33% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.67
Moderate Buy$6.5043.49% Upside
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
2.75
Moderate Buy$9.25111.67% Upside

Current Analyst Ratings Breakdown

Latest MOLN, PRME, EOLS, and ORGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$8.00
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00
5/27/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$10.00 ➝ $1.50
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.00
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
5/19/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
5/8/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evolus, Inc. stock logo
EOLS
Evolus
$266.27M2.16N/AN/A$0.09 per share99.00
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$5.65M26.20N/AN/A$3.99 per share0.92
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.19$0.21 per share22.05$2.09 per share2.17
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$3.85M152.82N/AN/A$1.37 per share3.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evolus, Inc. stock logo
EOLS
Evolus
-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%N/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$61.39M-$1.92N/AN/AN/AN/A-42.20%-38.12%8/25/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/7/2025 (Estimated)
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/A

Latest MOLN, PRME, EOLS, and ORGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/25/2025H1 2025
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$0.53N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01N/AN/AN/A$104.75 millionN/A
5/15/2025Q1 2025
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$0.3855-$0.50-$0.1145-$0.50N/AN/A
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$1.4533.09%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evolus, Inc. stock logo
EOLS
Evolus
22.00
2.34
2.16
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/A
15.28
15.28
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
N/A
6.50
6.50

Institutional Ownership

CompanyInstitutional Ownership
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
26.55%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
70.37%

Insider Ownership

CompanyInsider Ownership
Evolus, Inc. stock logo
EOLS
Evolus
6.10%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
5.93%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
22.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evolus, Inc. stock logo
EOLS
Evolus
17064.48 million60.54 millionOptionable
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
18040.38 million37.98 millionNot Optionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
234134.50 million100.38 millionOptionable

Recent News About These Companies

Prime Medicine Holds Special Stockholder Meeting
Prime Medicine Halts Sales Agreement Prospectus
Prime Medicine Announces Pricing of Public Offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evolus stock logo

Evolus NASDAQ:EOLS

$8.91 -0.20 (-2.20%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$6.59 -2.32 (-26.04%)
As of 08/5/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Molecular Partners stock logo

Molecular Partners NASDAQ:MOLN

$3.67 +0.02 (+0.44%)
Closing price 08/5/2025 02:58 PM Eastern
Extended Trading
$3.66 0.00 (-0.03%)
As of 08/5/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.53 -0.07 (-1.52%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$4.54 +0.00 (+0.11%)
As of 08/5/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Prime Medicine stock logo

Prime Medicine NYSE:PRME

$4.37 -0.13 (-2.89%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$4.36 -0.01 (-0.34%)
As of 08/5/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.